Bicycle Therapeutics Filed A Prospectus Supplement With Respect To Resale By Selling Securityholders
- SEC Filing
- SEC Filing
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/6/2024 | $35.00 | Outperform | RBC Capital Mkts |
8/7/2024 | $33.00 → $28.00 | Buy → Neutral | B. Riley Securities |
9/11/2023 | Neutral → Buy | B. Riley Securities | |
8/31/2022 | Outperform | Cowen | |
7/28/2022 | $30.00 | Overweight | Barclays |
7/6/2022 | $60.00 | Buy | Canaccord Genuity |
4/13/2022 | $62.00 → $33.00 | Buy → Neutral | B. Riley Securities |
4/7/2022 | $100.00 → $80.00 | Overweight | Cantor Fitzgerald |
Updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising 45% overall response rate (ORR), 11.1 months median duration of response and a generally well-tolerated safety profile EphA2-targeting BT5528 demonstrated an emerging differentiated safety profile and antitumor activity in patients with advanced solid tumors, including a 45% ORR in mUC 6.5 mg/m2 every two weeks dose expansion cohort Relatively low frequency and severity of treatment-related peripheral neuropathy following monotherapy with Bicycle Toxin Conjugates® zelenectide pevedotin and BT5528, with patients often able to continue therapy without modification
Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on September 3, 2024, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 29,500 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price per share equal to $21.50 per share, Bicycle Therapeutics' closing trading price on August 30, 2024, and will vest over fou
Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, Sept. 4; fireside chat at 8:30 a.m. ET 2024 Cantor Global Healthcare Conference on Wednesday, Sept. 18; fireside chat at 11:30 a.m. ET Live webcasts of the fireside chats will be accessible in the Investor section of the company's website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available following
- SEC Filing
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 550 points on Thursday. The Dow traded down 1.44% to 39,098.81 while the NASDAQ fell 0.39% to 16,735.32. The S&P 500 also fell, dropping, 0.69% to 5,270.47. Check This Out: How To Earn $500 A Month From Ross Stores Stock Ahead Of Q1 Earnings Leading and Lagging SectorsInformation technology shares rose by 1.5% on Thursday. In trading on Thursday, real estate shares fell by 1.3%. Top Headline BJ's Wholesale Club Holdings, Inc. (NYSE:BJ) reported better-than-expected results for its first quarter on Thursday. The company posted quarterly revenue growth of 4.1% year-on-year to $4
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 250 points on Thursday. The Dow traded down 0.65% to 39,414.01 while the NASDAQ rose 0.84% to 16,942.51. The S&P 500 also rose, gaining, 0.24% to 5,319.63. Check This Out: How To Earn $500 A Month From Ross Stores Stock Ahead Of Q1 Earnings Leading and Lagging SectorsInformation technology shares rose by 1.3% on Thursday. In trading on Thursday, real estate shares fell by 1.1%. Top Headline The S&P Global manufacturing PMI rose to 50.9 in May from 50 in April, while services PMI climbed to 54.8 in May from 51.3. The S&P Global composite PMI jumped to 54.4 in May compared to 51.3
RBC Capital Mkts initiated coverage of Bicycle Therapeutics with a rating of Outperform and set a new price target of $35.00
B. Riley Securities downgraded Bicycle Therapeutics from Buy to Neutral and set a new price target of $28.00 from $33.00 previously
B. Riley Securities upgraded Bicycle Therapeutics from Neutral to Buy
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director. Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ:BCYC), Kevin brings two decades of biotech and pharma experience to Macomics. In addition to his seat on Bicycle's board of directors, he is also a non-executive director of Alchemab Therapeutics Ltd. Kevin has led Bicycle Therapeutics since 2015, steering it through its strategic growth including various collaborations and financings including through its listing on NAS
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Alethia Young as its new Chief Financial Officer, effective July 17th. Ms. Young joins Bicycle from Graphite Bio, where she served as Chief Financial Officer, and previously served as senior biotech analyst and head of research at Cantor Fitzgerald. "We are thrilled to welcome Alethia to Bicycle and believe her experience and insights will make her an invaluable addition to our team," said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "Alethia is a se
- Santiago Arroyo, M.D., Ph.D., appointed Chief Development Officer - Jennifer Perry, Pharm.D., promoted to Senior Vice President, Commercial Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Development Officer, effective March 31. In addition, Jennifer Perry, PharmD, has been promoted to Senior Vice President, Commercial. Dr. Arroyo brings to Bicycle over 20 years of biopharmaceutical industry experience, leading the clinical development of therapeutics across multiple disease a
S-8 - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
10-Q - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024 Innovative study design allows for potential accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer Conference call and webcast today at 8 a.m. ET Bicycle Therapeutics (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the company will proceed with its plan to expedite development of BT8009 for metastatic bladder (urothelial) cancer following recent discussions with the U.S. Food and Drug Administration (FD
50% overall response rate (ORR) and 75% clinical benefit rate, including one complete response in urothelial cancer at the 5 mg/m2 dose on an intent-to-treat (ITT) basis As of January 2023, median duration of response (mDOR) is estimated to be approximately 14 months among urothelial cancer patients in the 5 mg/m2 cohort Confirmed RECIST responses in non-small cell lung cancer (NSCLC) and breast cancer patients Conference call scheduled for 8:00 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced monotherapy Phase I dose escalatio
- Company to Host Conference Call on February 14 at 8:00 a.m. ET - Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that monotherapy dose escalation results of the ongoing Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, will be presented at the 2023 American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, being held February 16-18, 2023 in San Francisco, California. On Tuesday, February 14, 2023 at 8:00 a.m. ET, the Company will host a conference call with BT8009 investigator Dr. Capucin
SC 13G - BICYCLE THERAPEUTICS plc (0001761612) (Subject)
SC 13D/A - BICYCLE THERAPEUTICS plc (0001761612) (Subject)
SC 13D - BICYCLE THERAPEUTICS plc (0001761612) (Subject)